Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia

Cancer
Azra RazaNaomi Galili

Abstract

The treatment of myelodysplastic syndromes (MDS) remains a challenge to the clinician despite recent advances. Many patients will either not respond or will have only limited and/or brief responses to single-agent therapy. Eventually, 30% of patients with MDS will progress and develop acute myeloid leukemia (AML). New strategies are needed for these patients. 5-Azacytidine (AZA) and thalidomide were administered to 40 patients with MDS or AML. AZA was given at a dose of 75 mg/m2 subcutaneously for 5 of 28 days together with thalidomide starting at a dose of 50 mg per day and increasing to 100 mg per. Six patients had refractory anemia (RA), 2 patients had RA with ringed sideroblasts, 10 patients had RA with excess blasts (RAEB), 1 patient had RAEB in transformation, 4 patients had chronic myelomonocytic leukemia, 1 patient had chronic idiopathic myelofibrosis, and 16 patients had AML. Thirty-six patients were evaluable for outcome. A hematologic improvement (HI) was observed in 15 of 36 patients (42%), stable disease was observed in 5 of 36 patients (14%), and 10 of 36 patients (28%) had disease progression. Six patients experienced complete remission (CR), 2 patients experienced an erythroid HI (HI-E), 1 patient experience an ...Continue Reading

References

Nov 1, 1978·Cancer·J H SaikiB Hoogstraten
Nov 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·A BhattacharjeeM Meyerson
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanJames F Holland
Nov 3, 2005·Nature Clinical Practice. Oncology·Shaji Kumar, Kenneth C Anderson
Apr 28, 2006·Nature Genetics·Michael ReichJill P Mesirov
May 20, 2006·Bioinformatics·Joshua GouldJill P Mesirov

❮ Previous
Next ❯

Citations

Feb 2, 2010·Cancer Chemotherapy and Pharmacology·Yong ChenSekhar Surapaneni
Jun 17, 2010·Nature Reviews. Clinical Oncology·Alfonso Quintás-CardamaGuillermo Garcia-Manero
Jan 18, 2012·Current Opinion in Hematology·Raphael Itzykson, Pierre Fenaux
May 29, 2010·Journal of Oncology·Michael MedingerAlexandar Tzankov
Jun 24, 2010·Journal of Angiogenesis Research·Michael Medinger, Klaus Mross
Oct 20, 2010·Drug Design, Development and Therapy·Carlos E VigilGuillermo Garcia-Manero
Apr 2, 2011·Advances in Therapy·Carmen Avellaneda MolinaPatricia Font
Aug 5, 2014·Cellular Reprogramming·Keerat KaurLeonard M Eisenberg
Mar 15, 2012·Cellular and Molecular Life Sciences : CMLS·Jean-Noël BastieLaurent Delva
Jun 15, 2011·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Asuka HoshiTakatoshi Koyama
Apr 2, 2009·Expert Opinion on Investigational Drugs·Camilla StapnesØystein Bruserud
May 22, 2010·Expert Opinion on Pharmacotherapy·Naomi Galili, Azra Raza
Dec 5, 2008·Expert Opinion on Investigational Drugs·George J Brewer
Mar 9, 2011·Expert Opinion on Investigational Drugs·Ernesto VignaFortunato Morabito
May 27, 2011·Cancer Treatment Reviews·Till Schoofs, Carsten Müller-Tidow
Sep 18, 2010·Trends in Pharmacological Sciences·Xiaojing YangPeter A Jones
Feb 13, 2010·Leukemia Research·V SantiniUNKNOWN Italian Society of Hematology
Jun 10, 2011·Cancer·Rubens CostaJohn Lister
Apr 30, 2013·Expert Opinion on Pharmacotherapy·Janusz KrawczykFrancis J Giles
Apr 15, 2015·Critical Reviews in Oncology/hematology·Christopher B BentonGuillermo Garcia-Manero
Mar 25, 2014·Lancet·Lionel AdèsPierre Fenaux
Aug 6, 2011·Clinical Lymphoma, Myeloma & Leukemia·Ali Al-AmeriAlfonso Quintás-Cardama
Feb 3, 2016·Therapeutic Advances in Hematology·Kazusa Ishii, Austin J Barrett
Apr 23, 2013·Therapeutic Advances in Hematology·Cyrus KhanJames M Rossetti
Oct 20, 2018·Expert Review of Hematology·Ramy Rahmé, Lionel Adès
Oct 1, 2019·British Journal of Haematology·Pierre FenauxLionel Ades
Dec 14, 2011·Hematology·Lionel Adès, Pierre Fenaux
Oct 4, 2011·Journal of Biomolecular Screening·Jason M FoulksSteven B Kanner
Sep 10, 2020·Cancers·Antonio PiccolomoFrancesco Albano
Sep 21, 2012·Oncology Reports·Guanhua SongGuosheng Jiang
Jan 9, 2020·British Journal of Clinical Pharmacology·Justine PerinoSophie Dimicoli-Salazar
Feb 25, 2011·Cellular Signalling·Juan RenShi-Wen Jiang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.